echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Cyhono-Pharmaceutical seishemal anti-peptides for injection seisido approved

    Cyhono-Pharmaceutical seishemal anti-peptides for injection seisido approved

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Drug Indications: Treatment of advanced solid tumors, such as lung, bowel, stomach, etcResearch: After the company obtained the approval, actively promote pharmaceutical and clinical work, has officially launched the Phase I clinical trial workSimilar drug market conditions: In 2004, the first antivascular-generated antibody drug belavite was introduced in the United States for the treatment of metastatic colon cancer and moreThe experiments on angiogenesis anti-peptide efficacy showed that different doses of angiogenesis peptides had inhibitory effectonon on the growth of gastric cancer cells BGC-823, lung cancer cells PG and bowel cancer cells HT-29, and also inhibited the almanocre cell B16F10 lung metastasis.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.